Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease
Open accessAbstract
To elucidate the relevance of gut dysbiosis in Parkinson’s disease (PD) in disease progression, we made random forest models to predict the progression of PD in two years by gut microbiota in 165 PD patients. The area under the receiver operating characteristic curves (AUROCs) of gut microbiota-based models for Hoehn & Yahr (HY) stages 1 and 2 were 0.799 and 0.705, respectively. Similarly, gut microbiota predicted the progression of Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) III scores in an early stage of PD with AUROC = 0.728. Decreases of short-chain fatty acid-producing genera, Fusicatenibacter , Faecalibacterium , and Blautia , as well as an increase of mucin-degrading genus Akkermansia , predicted accelerated disease progression. The four genera remained unchanged in two years in PD, indicating that the taxonomic changes were not the consequences of disease progression. PD patients with marked gut dysbiosis may thus be destined to progress faster than those without gut dysbiosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Diminished SCFA-producing species and SCFA levels are consistently reported in prodromal PD and PD patients compared with healthy controls, and may be correlated with clinical severity of PD.
“These findings are in concordance with a substantial body of literature that consistently reports diminished SCFAs-producing species and SCFA levels in prodromal stage of PD and PD patients compared to healthy controls, which may be correlated with the clinical severity of PD.52,322–331”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [322]
A reduction in Fusicatenibacter, Blautia and Faecalibacterium, together with an increased presence of Akkermansia, correlates with a faster progression of Parkinson's disease.
“a machine learning approach accounting for the abundance of various gut microbial species revealed that a reduction in Fusicatenibacter, Blautia and Faecalibacterium, together with an increased presence of Akkermansia, correlates with a faster progression of the disease [166]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055 · see citing works
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742 · see citing works
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653 · see citing works
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,756 · see citing works
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · see citing works
The SILVA and “All-species Living Tree Project (LTP)” taxonomic frameworks
Yilmaz, P., Parfrey, L., Yarza, P., Gerken, J., Pruesse, E., Quast, C., Schweer, T., Peplies, J., Ludwig, W., & Glöckner, F. (2013) · Nucleic Acids Res. · doi:10.1093/nar/gkt1209 · Cited by 3,547 · see citing works
Desai, M. S., Seekatz, A. M., Koropatkin, N. M., Kamada, N., Hickey, C. A., Wolter, M., Pudlo, N. A., Kitamoto, S., Terrapon, N., Muller, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.043 · Cited by 2,805 · see citing works
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357 · see citing works
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204 · see citing works
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · see citing works
Dao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., Kayser, B. D., Levenez, F., Chilloux, J., Hoyles, L., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308778 · Cited by 1,931 · see citing works
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550 · see citing works
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · see citing works
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354 · see citing works
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · see citing works
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159 · see citing works
The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet
Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., & Hsiao, E. Y. (2018) · Cell · doi:10.1016/j.cell.2018.04.027 · Cited by 1,057 · see citing works
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021 · see citing works
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · see citing works
Stebbins, G. T., Goetz, C. G., Burn, D. J., Jankovic, J. J., Khoo, T. K., & Tilley, B. C. (2013) · Movement Disorders · doi:10.1002/mds.25383 · Cited by 946 · see citing works
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925 · see citing works
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · see citing works
Romano, S., Savva, G. M., Bedarf, J. R., Charles, I. G., Hildebrand, F., & Narbad, A. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00156-z · Cited by 707 · see citing works
Potential roles of gut microbiome and metabolites in modulating ALS in mice
Blacher, E., Bashiardes, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., Kleimeyer, C., Moresi, C., Harnik, Y., Zur, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1443-5 · Cited by 700 · see citing works
Bedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642 · see citing works
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554 · see citing works
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523 · see citing works
Self-citationThenganatt, M. A., & Jankovic, J. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6233 · Cited by 510 · see citing works
Analysis of Gut Microbiota in Patients with Parkinson’s Disease
Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y. B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., et al. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3700-7 · Cited by 487 · see citing works
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466 · see citing works
Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases
Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25020 · Cited by 464 · see citing works
Xu, Y., Wang, N., Tan, H.-Y., Li, S., Zhang, C., & Feng, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00219 · Cited by 420 · see citing works
Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409 · see citing works
Li, W., Wu, X., Hu, X., Wang, T., Liang, S., Duan, Y., Jin, F., & Qin, B. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9001-4 · Cited by 406 · see citing works
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393 · see citing works
<scp>Meta‐Analysis</scp> of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370 · see citing works
Self-citationGut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361 · see citing works
Grimm, D. G., Azencott, C., Aicheler, F., Gieraths, U., MacArthur, D. G., Samocha, K. E., Cooper, D. N., Stenson, P. D., Daly, M. J., Smoller, J. W., et al. (2015) · Human Mutation · doi:10.1002/humu.22768 · Cited by 356 · see citing works
Baxter, N. T., Ruffin, M. T., Rogers, M. A. M., & Schloss, P. D. (2016) · Genome Medicine · doi:10.1186/s13073-016-0290-3 · Cited by 354 · see citing works
Bloch, A., Probst, A., Bissig, H., Adams, H., & Tolnay, M. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00727.x · Cited by 330 · see citing works
Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., & Takahashi, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0257-5 · Cited by 328 · see citing works
Microbiota composition and metabolism are associated with gut function in Parkinson's disease
Cirstea, M. S., Yu, A. C., Golz, E., Sundvick, K., Kliger, D., Radisavljevic, N., Foulger, L. H., Mackenzie, M., Huan, T., Finlay, B. B., et al. (2020) · Movement Disorders · doi:10.1002/mds.28052 · Cited by 326 · see citing works
Gut microbiota in Parkinson disease in a northern German cohort
Hopfner, F., Künstner, A., Müller, S. H., Künzel, S., Zeuner, K. E., Margraf, N. G., Deuschl, G., Baines, J. F., & Kuhlenbäumer, G. (2017) · Brain Research · doi:10.1016/j.brainres.2017.04.019 · Cited by 318 · see citing works
Parkinson's Disease: The Dual Hit Theory Revisited
Hawkes, C. H., Del Tredici, K., & Braak, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04365.x · Cited by 303 · see citing works
Li, J.-M., Yu, R., Zhang, L.-P., Wen, S.-Y., Wang, S.-J., Zhang, X.-Y., Xu, Q., & Kong, L.-D. (2019) · Microbiome · doi:10.1186/s40168-019-0713-7 · Cited by 300 · see citing works
Structural alterations of the intestinal epithelial barrier in Parkinson’s disease
Clairembault, T., Leclair‐Visonneau, L., Coron, E., Bourreille, A., Dily, S. L., Vavasseur, F., Heymann, M., Neunlist, M., & Derkinderen, P. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0196-0 · Cited by 292 · see citing works
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease
Vascellari, S., Palmas, V., Melis, M., Pisanu, S., Cusano, R., Uva, P., Perra, D., Madau, V., Sarchioto, M., Oppo, V., et al. (2020) · mSystems · doi:10.1128/msystems.00561-20 · Cited by 291 · see citing works
Gut microbiota in patients with Parkinson's disease in southern China
Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.007 · Cited by 253 · see citing works
The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet
Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., & Hsiao, E. Y. (2018) · Cell · doi:10.1016/j.cell.2018.06.051 · Cited by 224 · see citing works
Dysbiosis of gut microbiota in a selected population of Parkinson's patients
Pietrucci, D., Cerroni, R., Unida, V., Farcomeni, A., Pierantozzi, M., Mercuri, N. B., Biocca, S., Stefani, A., & Desideri, A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.06.003 · Cited by 217 · see citing works
Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates
Arotcarena, M.-L., Dovero, S., Prigent, A., Bourdenx, M., Camus, S., Porras, G., Thiolat, M.-L., Tasselli, M., Aubert, P., Kruse, N., et al. (2020) · Brain · doi:10.1093/brain/awaa096 · Cited by 210 · see citing works
Prognostic factors for the progression of Parkinson's disease: A systematic review
Post, B., Merkus, M. P., de Haan, R. J., Speelman, J. D., & CARPA Study Group (2007) · Movement Disorders · doi:10.1002/mds.21537 · Cited by 206 · see citing works
Manfredsson, F. P., Luk, K. C., Benskey, M. J., Gezer, A., Garcia, J., Kuhn, N. C., Sandoval, I. M., Patterson, J. R., O'Mara, A., Yonkers, R., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.008 · Cited by 199 · see citing works
Park, J., Wang, Q., Wu, Q., Mao‐Draayer, Y., & Kim, C. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-45311-y · Cited by 196 · see citing works
Propagation of pathological α-synuclein in marmoset brain
Shimozawa, A., Ono, M., Takahara, D., Tarutani, A., Imura, S., Masuda‐Suzukake, M., Higuchi, M., Yanai, K., Hisanaga, S., & Hasegawa, M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0413-0 · Cited by 190 · see citing works
Gut Microbiota Differs Between Parkinson’s Disease Patients and Healthy Controls in Northeast China
Li, C., Cui, L., Yang, Y., Miao, J., Zhao, X., Zhang, J., Cui, G., & Zhang, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00171 · Cited by 178 · see citing works
Zhang, J., Ni, Y., Qian, L., Fang, Q., Zheng, T., Zhang, M., Gao, Q., Zhang, Y., Ni, J., Hou, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202100536 · Cited by 168 · see citing works
Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.035 · Cited by 162 · see citing works
Remely, M., Hippe, B., Zanner, J., Aumueller, E., Brath, H., & Haslberger, A. G. (2016) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530316666160831093813 · Cited by 143 · see citing works
AUC-RF: A New Strategy for Genomic Profiling with Random Forest
Calle, M. L., Urrea, V., Boulesteix, A., & Malats, N. (2011) · Human Heredity · doi:10.1159/000330778 · Cited by 138 · see citing works
Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · mSystems · doi:10.1128/msystems.00797-20 · Cited by 133 · see citing works
Self-citationThe diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease
Gibbons, C. H., García, J. M., Wang, N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002919 · Cited by 115 · see citing works
Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease
Chiang, H., & Lin, C. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18067 · Cited by 104 · see citing works
Pesticides and Parkinson’s disease: Current and future perspective
Islam, M. S., Azim, F., Saju, H., Zargaran, A., Shirzad, M., Kamal, M., Fatema, K., Rehman, S., Azad, M. A. M., & Ebrahimi‐Barough, S. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.101966 · Cited by 94 · see citing works
Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson’s Disease
Cersosimo, M. G. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/476041 · Cited by 61 · see citing works
Prognostic factors for early mortality in Parkinson's disease
Oosterveld, L. P., Allen, J. C., Reinoso, G., Seah, S., Tay, K. Y., Au, W., & Tan, L. C. S. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.011 · Cited by 61 · see citing works
Altered gut microbiome and metabolome in patients with multiple system atrophy
Tan, A. H., Chong, C. W., Song, S., Teh, C. S. J., Yap, I. K. S., Loke, M. F., Tan, Y. Q., Yong, H.-S., Mahadeva, S., Lang, A. E., et al. (2017) · Movement Disorders · doi:10.1002/mds.27203 · Cited by 52 · see citing works
Ueyama, J., Oda, M., Hirayama, M., Sugitate, K., Sakui, N., Hamada, R., Ito, M., Saito, I., & Ohno, K. (2019) · Analytical Biochemistry · doi:10.1016/j.ab.2019.113508 · Cited by 38 · see citing works
Self-citationDevelopment and validation of prognostic survival models in newly diagnosed Parkinson's disease
Macleod, A. D., Dalen, I., Tysnes, O., Larsen, J. P., & Counsell, C. E. (2017) · Movement Disorders · doi:10.1002/mds.27177 · Cited by 31 · see citing works
Tsiouris, Κ. Μ., Konitsiotis, S., Koutsouris, D., & Fotiadis, D. I. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101807 · Cited by 31 · see citing works
Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease
Bordelon, Y. M., Hays, R. D., Vassar, S. D., et al. (2011) · Parkinson s Disease · doi:10.4061/2011/967839 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · see citing works
<i>Ruminococcus gnavus</i> : friend or foe for human health
Crost, E. H., Coletto, E., Bell, A., & Juge, N. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad014 · Cited by 335 · see citing works
Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial
Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2305 · Cited by 128 · see citing works
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
- Authors
- Nishiwaki, H., Ito, M., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Yoshida, T., Hanada, H., Takeuchi, I., Katsuno, M., Hirayama, M., & Ohno, K.
- Affiliations
- Nagoya University (JP)
- Iwate Medical University (JP)
- Fukuoka University (JP)
- Nagoya Institute of Technology (JP)
- RIKEN (JP)
- Corresponding author
- Hirayama, Masaaki
- Ohno, Kinji
- ORCID
- Venue
- npj Parkinson's Disease
- Published
- 2022-06-01
- Volume
- 8
- Issue
- 1
- Pages
- 65-65
- ISSN
- 2373-8057 (ISSN-L)
- PMC
- PMC9160257
- OpenAlex
- W4281748741
- Cited by
- 116
- References
- 74
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 32 · 2023: 26 · 2022: 7
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- npj Parkinson s Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- MEXT | Japan Society for the Promotion of Science (JP21H03561)
- Ministry of Health, Labour and Welfare (20FC1036)
- Japan Agency for Medical Research and Development (JP21gm1010002, JP21ek0109488, and JP21bm0804005)
- National Center of Neurology and Psychiatry (2-5)
- Smoking Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut microbiota, gut dysbiosis, short-chain fatty acids, mucin-degrading bacteria, Akkermansia, Faecalibacterium, Blautia, Fusicatenibacter, disease progression prediction, Hoehn and Yahr stage, MDS-UPDRS III, early-stage Parkinson's disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
